Showing posts with label injections. Show all posts
Showing posts with label injections. Show all posts

Monday, 19 August 2013

Insulin pumps 'better than injections' for type 1 diabetes

Featured Article
Academic Journal
Main Category: Diabetes
Also Included In: Pediatrics / Children's Health
Article Date: 19 Aug 2013 - 0:00 PDT Current ratings for:
Insulin pumps 'better than injections' for type 1 diabetes
not yet ratednot yet rated

Researchers say that insulin pumps are more effective at controlling type 1 diabetes in children and cause fewer complications than insulin injections, having completed the longest and largest study of insulin pumps to date.

According to the researchers at the Princess Margaret Hospital for Children in Australia, the use of pump therapy has increased over the last 15 years, particularly in children.

Pump therapy involves having a catheter placed under the skin to deliver short-acting doses of insulin around the clock. The insulin pump delivers the dosage at two levels: at the basal rate, the normal level of blood insulin needed when a person with diabetes has not eaten or is asleep; and the bolus rate, the level of insulin needed when a diabetic eats.

The study, published in the journal of the European Association for the Study of Diabetes, analyzed 345 children with type 1 diabetes undergoing pump therapy, and the same number of children who treat their diabetes with injections.

All children were aged between 2 and 19-years-old and had a mean diabetes duration of 4.1 years at the start of pump therapy. The follow-up mean duration period for the children was 3.5 years.

Results of the analysis revealed that the use of insulin pumps reduced episodes of severe hypoglycemia - dangerously low blood glucose - from 14.7 events in every 100 patients a year, to 7.2 episodes.

Numbers of severe hypoglycemic events in children using insulin injections, meanwhile, went up over the same period, from 6.8 events in every 100 patients per year, to 10.2 episodes.

Additionally, the rate of admission for diabetic ketoacidosis was lower in children using pump therapy at 2.3 events per every 100 patients per year, compared with 4.7 events per every 100 patients per year using insulin injections.

Dr. Elizabeth Davis, an associate professor at the Princess Margaret Hospital for Children, says the results of this study are strong due to its large population-based sample over a long period of time.

"This is the largest study of insulin pump use in children. It also has the longest follow-up period of any study of insulin pump therapy in children," she says.

Dr. Davis adds:

"Our data confirm that insulin pump therapy provides an improvement in glycemic control which is sustained for at least seven years.

Although this is not a randomized trial, it is 'real life' experience in a large population-based sample over a prolonged time period and, as such, provides important information."

In other research on insulin pumps, presented at the American Diabetes Association 73rd Scientific Sessions in Chicago this year, one model of insulin pump was found to reduce nocturnal hypoglycemia without affecting glycated hemoglobin levels.

The authors of this latest research note that of the children using pump therapy, 38 stopped the treatment during the course of the study.

They explain that some children may have stopped because they became tired of the extra attention taken to manage the pump. Children may also be concerned about its physical appearance.

Written by Honor Whiteman


Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today Visit our diabetes section for the latest news on this subject. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study; Stephanie Johnson, Matthew Cooper, Timothy Jones and Elizabeth Davis, Diabetologia, August 18, 2013. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Whiteman, Honor. "Insulin pumps 'better than injections' for type 1 diabetes." Medical News Today. MediLexicon, Intl., 19 Aug. 2013. Web.
19 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Insulin pumps 'better than injections' for type 1 diabetes'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Saturday, 17 August 2013

Stem cell spine injections for MS - trial approved

Featured Article
Main Category: Multiple Sclerosis
Also Included In: Stem Cell Research
Article Date: 17 Aug 2013 - 0:00 PDT Current ratings for:
Stem cell spine injections for MS - trial approved
5 stars5 stars

The US Food and Drug Administration (FDA) has approved a new clinical trial of a groundbreaking strategy using stem cells for the treatment of MS (multiple sclerosis).

Researchers from the Tisch MS Research Center of New York say the FDA has granted approval to begin early clinical investigation (phase 1 trial) of autologous neural stem cells in the treatment of MS.

Multiple sclerosis is a chronic disease that attacks the central nervous system (the spinal cord, optic nerves and brain). Common symptoms are numbness of the limbs, but more severe cases can lead to paralysis and blindness.

According to the Multiple Sclerosis Foundation, there are currently between 350,000 to 500,000 people in the US who have been diagnosed with MS, and 200 people are diagnosed with the disease every week.

The new regenerative strategy will involve using autologous, mesenchymal stem cell-derived neural progenitor cells (MSC-NPs), which will be harvested from the bone marrow of 20 MS patients who meet the criteria for the trial.

The stem cells will then be injected into the cerebrospinal fluid that surrounds the spinal cords of the patients.

The main objective of the clinical trial, the researchers say, is to determine the safety of the treatment, while the secondary objective is to measure the effectiveness.

The injections will be repeated at 3-month intervals, with their safety and efficacy frequently monitored through follow-up visits. After the final injection, patients will be monitored for up to 27 months.

Preclinical testing of this procedure showed that after injecting the stem cells, brain inflammation was reduced in seven MS patients, myelin was repaired (an insulating layer that forms around nerves), and protection of the neuronal structure and function of the brain was improved.

Dr. Saud Sadiq, senior research scientist at Tisch MS Research Center of New York, says:

"This study provides a hope that established disability may be reversed in MS."

Similar trials but with larger number of patients (phase 2) have already been under way in the UK. In 2011, UK scientists received £1 million from the MS Society and the UK Stem Cell Foundation (UKCSF) towards research investigating whether stem cells can slow, stop or reverse brain and spinal cord damage in MS patients.

Dr. Sadiq says of this most recent trial in the US:

"To my knowledge, this is the first FDA-approved stem cell trial in the United States to investigate direct injection of stem cells into the cerebrospinal fluid of MS patients, and represents an exciting advance in MS research and treatment."

The clinical trial will begin enrolling patients once ethical approval has been granted and funding secured.

Written by Honor Whiteman


Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today Visit our multiple sclerosis section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Whiteman, Honor. "Stem cell spine injections for MS - trial approved." Medical News Today. MediLexicon, Intl., 17 Aug. 2013. Web.
17 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Stem cell spine injections for MS - trial approved'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here